Long-time Catalyst Intellectual Property client Aroa Biosurgery Limited is to list on the ASX (Australian Securities Exchange).
Aroa’s business is based on soft tissue reconstruction and the healing of complex wounds. Aroa manufactures products from a material derived from sheep forestomach which acts as a matrix for new tissue generation. Aroa’s products are sold primarily in the United States and are used for treating chronic wounds, hernia surgery, soft tissue repair and breast reconstruction.
The IPO (initial public offering) values Aroa at A$225m and is expected to raise $45m. Share trading will commence on 30 July 2020. See here for more information.
Partner at Catalyst Intellectual Property, Greg Lynch, wrote the intellectual property report for the IPO prospectus which has now been lodged at the ASX.
Catalyst Intellectual Property counts four high profile publicly listed New Zealand biotechnology companies among its clients – The a2 Milk Company Limited, Pacific Edge Limited, Aroa Biosurgery Limited and Livestock Improvement Corporation Limited.